TEK PHARM. LTDActive

Company number 14069739Private limited companyIncorporated 2022

Key figures

£58,958+68.1%
Net assets 2024/25
+125.3%
Average annual growth 2022/23–2024/25
020 k40 k60 k2022/232023/242024/25

Like most small UK companies, TEK PHARM. LTD does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
050 k100 k2022/232023/242024/25
Filed accounts2022/23–2024/25
2022/232023/242024/25
Cash at bank and in hand41,34145,0281,793
Total assets41,34166,65392,101
Total liabilities29,72531,58933,143
Net assets / total equity11,61635,06458,958
Average number of employees111

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Principal activity

Accounts 2025

The company's principal activity continues to be that of providing human health activities services.

As described in the company's latest filed accounts.

Summary: TEK PHARM. LTD

Company

TEK PHARM. LTD is a private limited company registered with Companies House under company number 14069739. It was incorporated on 26 Apr 2022. Its status is active. The registered office is in Morden (SM4). Its nature of business (SIC 2007) is other human health activities (86900).

Accounts

The latest accounts in the database are for 2024/25 (period ending 31 May 2025); the company files abridged accounts (unaudited). Net assets were £58,958, up 68.1% on the previous year. Cash at bank and in hand was £1,793. Total assets were £92,101 and total liabilities £33,143. The company had an average of 1 employee. Figures are available for 3 financial years (2022/23–2024/25).

Control and charges

One person with significant control is registered.

Filing deadlines

The next accounts are due by 28 Feb 2027. The next confirmation statement is due by 2 Jul 2027.